Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Клиническая эффективность и безопасность длительно действующих бронходилататоров при хронической обструктивной болезни легких
Клиническая эффективность и безопасность длительно действующих бронходилататоров при хронической обструктивной болезни легких
И.В.Лещенко, Н.А.Эсаулова. Клиническая эффективность и безопасность длительно действующих бронходилататоров при хронической обструктивной болезни легких. Consilium Medicum. Пульмонология (Прил.). 2013; 1: 22-27.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (Updated 2013).
2. Barnes PJ, Stockley RA. COPD: Current Therapeutic Interventions and Future Approaches. Eur Respir J 2005; 25 (6): 1084–106.
3. Falk JA, Kadiev S, Griner GJ. Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thoracic Soc 2008; 5: 543–8.
4. Tashkin, D, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004; 125: 249–59.
5. Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543–54.
6. Calverley PM, Anderson JA, Celli B et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 22; 356 (8): 775–89.
7. Van Noord JA, Aumann JL. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26: 214–22.
8. O’Donnell DE, Laveneziana P. Dyspnea and activity limitation in COPD: mechanical factors. COPD 2007; 4: 225–36.
9. Acerbi D, Brambilla G, Kottakis I. Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology. Pulm Pharmacol Ther 2007; 20 (3): 290–303.
10. Häussermann S, Acerbi D, Brand P et al. Lung deposition of formoterol HFA (Atimos/Forair) in healthy volunteers, asthmatic and COPD patients. J Aerosol Med 2007; 20 (3): 331–41.
11. Bousquet J, Huchon G. Leclerc V et al. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing Formoterol-HFA (pMDI) versus Formoterol-DPI (AerolizerR) and Placebo (pMDI or Aerolizer®) in Asthmatic Patients. Respiration 2005; 72 (Suppl. 1): 6–12.
12. Meyer T, Brand P, Ehlich H et al. Deposition of Foradil P in human lungs: comparison of in vitro and in vivo data. J Aerosol Med 2004; 17 (1): 43–9.
13. Terzano C, Petroianni A, Conti V et al. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir Med 2008; 102 (12): 1701–7.
14. Anthonisen NR, Manfreda J, Warren CPW. Antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204.
15. Jones PW, Harding G, Berry P et al. Development and first validation of the COPD assessment test. Eur Respir J 2009; 34: 648–54.
2. Barnes PJ, Stockley RA. COPD: Current Therapeutic Interventions and Future Approaches. Eur Respir J 2005; 25 (6): 1084–106.
3. Falk JA, Kadiev S, Griner GJ. Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thoracic Soc 2008; 5: 543–8.
4. Tashkin, D, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004; 125: 249–59.
5. Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543–54.
6. Calverley PM, Anderson JA, Celli B et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 22; 356 (8): 775–89.
7. Van Noord JA, Aumann JL. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26: 214–22.
8. O’Donnell DE, Laveneziana P. Dyspnea and activity limitation in COPD: mechanical factors. COPD 2007; 4: 225–36.
9. Acerbi D, Brambilla G, Kottakis I. Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology. Pulm Pharmacol Ther 2007; 20 (3): 290–303.
10. Häussermann S, Acerbi D, Brand P et al. Lung deposition of formoterol HFA (Atimos/Forair) in healthy volunteers, asthmatic and COPD patients. J Aerosol Med 2007; 20 (3): 331–41.
11. Bousquet J, Huchon G. Leclerc V et al. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing Formoterol-HFA (pMDI) versus Formoterol-DPI (AerolizerR) and Placebo (pMDI or Aerolizer®) in Asthmatic Patients. Respiration 2005; 72 (Suppl. 1): 6–12.
12. Meyer T, Brand P, Ehlich H et al. Deposition of Foradil P in human lungs: comparison of in vitro and in vivo data. J Aerosol Med 2004; 17 (1): 43–9.
13. Terzano C, Petroianni A, Conti V et al. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir Med 2008; 102 (12): 1701–7.
14. Anthonisen NR, Manfreda J, Warren CPW. Antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204.
15. Jones PW, Harding G, Berry P et al. Development and first validation of the COPD assessment test. Eur Respir J 2009; 34: 648–54.
Авторы
И.В.Лещенко1, 2, Н.А.Эсаулова2
1 ГБОУ ВПО Уральская государственная медицинская академия Минздрава РФ, Екатеринбург;
2 ООО Медицинское объединение «Новая больница», Екатеринбург
1 ГБОУ ВПО Уральская государственная медицинская академия Минздрава РФ, Екатеринбург;
2 ООО Медицинское объединение «Новая больница», Екатеринбург
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.